
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
ERT announced it has launched a certification program for Phase I investigative sites conducting cardiac safety studies. This program trains sites to collect precise cardiac safety data by using ERT’s proprietary Expert Precision QT approach so that trial sponsors and CROs can determine the safety of their compounds earlier in development, which can save significant time and money.
Read the full release






